Publicacions en col·laboració amb investigadors/es de Eli Lilly and Company (8)

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2012

  1. Delphi consensus on the physical health of patients with schizophrenia: Evaluation of the recommendations of the Spanish societies of psychiatry and biological psychiatry by a panel of experts

    Actas Espanolas de Psiquiatria, Vol. 40, Núm. 3, pp. 114-128

2011

  1. Clinical meaningful outcomes in schizophrenia: Remission and recovery

    Revista de Psiquiatria y Salud Mental, Vol. 4, Núm. 1, pp. 53-65

2007

  1. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study

    European Psychiatry, Vol. 22, Núm. 8, pp. 490-498

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481

  2. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48